

University of Perugia

**Yuri Rukazenkov** Brand Physician IRESSA - Global Clinical Development - AstraZeneca, Macclesfield, UK

**Giulio Vittorio Scagliotti** Faculty of Medicine San Luigi Gonzaga - University of Turin - Director of Department of Lung Oncology - Azienda Ospedaliera S. Luigi - Orbassano (TO)

**Umberto Tirelli** Director Medical Oncology A Unit CRO - National Cancer Institute - Aviano (PN)

**Giuseppe Toffoli** Director Experimental and Clinical Pharmacology Unit CRO - National Cancer Institute- Aviano (PN)

**Carlo Tomino** Head of Clinical Trial - Italian Medicines Agency - Roma

**Mauro Gaetano Trovò** Director Radiotherapy Unit CRO - National Cancer Institute - Aviano (PN)



## SEDE DEL CONGRESSO

Sala Convegni  
Centro di Riferimento Oncologico - IRCCS  
Via Franco Gallini, 2 - 33081 Aviano

## COME RAGGIUNGERE IL CRO

**IN AUTO** Autostrada A-27 uscita Conegliano, Autostrada A-28 uscita Sacile

**IN TRENO** Arrivo alla stazione di Pordenone e poi bus per il CRO di Aviano, oppure taxi (da Pordenone ad Aviano ci sono circa 20 km)

**IN AEREO** Aeroporto "Marco Polo" - Venezia (dall'aeroporto ad Aviano ci sono circa 90 km)

Presidente del convegno:  
**Giuseppe Toffoli**

## COMITATO ORGANIZZATORE

**Giuseppe Toffoli (CRO-Aviano)**

**Tullio Giraldi (SIF - Friuli Venezia Giulia)**

## SEGRETERIA SCIENTIFICA

**Erika Cecchin** - SOC Farmacologia Sperimentale e Clinica - Centro di Riferimento Oncologico  
Via F. Gallini, 2 - 33081 Aviano (Pn)  
tel: 0434-659667 - fax: 0434-659659  
e-mail: ececchin@cro.it

## SEGRETERIA ORGANIZZATIVA

The office srl (iscrizioni)  
Via San Nicolò, 14 - 34121 Trieste  
tel: 040-368343 - fax: 040-368808  
e-mail: cancertherapy09@theoffice.it  
sito web: www.theoffice.it

Referente CRO: **Anna Vallerugo** - SOC Farmacologia Sperimentale e Clinica e-mail: avallerugo@cro.it

*Sono stati richiesti crediti ECM per le seguenti qualifiche:  
medico, farmacista, chimico, biologo, infermiere, TSLB.  
Il convegno si terrà prevalentemente in lingua italiana.*

**diatech**  
the pharmacogenetics company

**Lilly**  
Risposte che contano

**sanofi aventis**  
La salute. La cosa più importante

**Pfizer Oncology**



Provincia di Pordenone

**From  
pharmacogenetics  
to personalized cancer  
therapy**

**December 14th 2009**

**Sala convegni CRO-Aviano**



**CRO AVIANO**  
1984 2009



## programme

8.30-9.00 REGISTRATION

9.00-9.15 WELCOME

Paolo De Paoli, Scientific Director CRO Authorities

**SESSION 1:** 9.15-10.45

### Pharmacogenetics & Public Health

Chairpersons: Mark J Ratain, Carlo Tomino

9.15-10.05 Mark J Ratain  
Pharmacogenomics: challenges and opportunities

10.05-10.25 Giuseppe Novelli  
The FDA and the EMEA Guidance for Industry and regulatory needs

10.25-10.45 Achille Caputi  
Economic consequences of ADRs and potential impact of pharmacogenomics

10.45-11.00 COFFEE-BREAK

**SESSION 2:** 11.00-13.30

### Individualizing cancer therapy

Chairpersons: Tullio Giraldi, Giuseppe Toffoli

11.00-11.20 Federico Innocenti  
Application of genome-wide technologies to identify novel candidate genes of treatment outcome

11.20-11.40 Giuseppe Toffoli  
Pharmacogenetics for individualizing dosing: clinical utility

11.40-12.00 Giulio Vittorio Scagliotti  
Pharmacogenetics: a prognostic and predictive marker

12.00-12.20 Antonella Pirazzoli  
Pharmacogenetics and future drug development and delivery

12.20-12.40 Michael Lahn  
The Pharmacogenomic Relevance of Targeting Survivin In Cancer Patients: Lessons from a First in Human Dose (FHD) Study of the Survivin Antisense Oligonucleotide

12.40-13.00 Martin Potgeter  
From bench to bedside: how new tools for pharmacogenetics/genomics improve clinical diagnosis

13.00-13.30 ROUND TABLE (AIOM, SIF, AIFA)

13.30-14.30 LUNCH

**SESSION 3:** 14.30-16.30

### Integration of Pharmacogenomics in the Clinical practice 1

Chairpersons: Umberto Tirelli, Giampiero Fasola, Mauro G. Trovò

14.30-14.50 Yuri Rukazenkov  
EGFR pharmacogenomics and gefitinib clinical development

14.50-15.10 Federico Cappuzzo  
Kras and pharmacogenomic markers of response to EGFR inhibitors

15.10-15.30 Alfredo Budillon  
Pharmacogenetics/omics of anti-angiogenetic drugs

15.30-15.50 Enrico Mini  
Pharmacogenetics of fluoropyrimidines and anti-folate therapy

15.50-16.10 Erika Cecchin  
Genetic profiles of radiotherapy individualization

16.10-16.30 Henk-Jan Guchelaar  
Pharmacogenetics in oncology: from monogenetic associations to complex trait

16.30-16.40 COFFEE-BREAK

**SESSION 4:** 16.40-18.00

### Integration of Pharmacogenomics in the Clinical practice 2

Chairpersons: Andrea Veronesi, Sergio Frustaci

16.40-17.00 Fabio Puglisi  
Genomics profiles for breast cancer treatment tailoring

17.00-17.20 Carmine Pinto  
The Italian Project for the detection of KRAS-mutations in advanced colorectal cancer

17.20-17.40 Silvana Canevari  
Genomics profiles for ovarian cancer treatment tailoring

17.40-18.00 Roberta Bertorelle  
Molecularly targeted therapy in the GIST treatment

## affiliations

**Roberta Bertorelle** Molecular Immunology and Oncology - Istituto Oncologico Veneto - Padova

**Alfredo Budillon** Director of Experimental Pharmacology Unit Fondazione G. Pascale - Istituto Nazionale Tumori- Napoli

**Silvana Canevari** Head, Unit of Molecular Therapies - Experimental Oncology Department - Istituto Nazionale dei Tumori - Milano

**Federico Cappuzzo** Medical Oncology - Istituto Clinico Humanitas - Milano

**Achille Patrizio Caputi** President of Italian Society of Pharmacology (SIF) - Director of Clinical and Experimental Department of Medicine and Pharmacology - University of Messina

**Erika Cecchin** Experimental and Clinical Pharmacology CRO - National Cancer Institute - Aviano (PN)

**Giampiero Fasola** Director Medical Oncology Azienda Ospedaliera Santa Maria degli Angeli - Udine

**Sergio Frustaci** Director Medical Oncology B CRO - National Cancer Institute - Aviano (PN)

**Tullio Giraldi** Professor of Pharmacology Faculty of Medicine - University of Trieste

**Henk-Jan Guchelaar** Professor of Clinical Pharmacy Chair. Dept. Clinical Pharmacy & Toxicology Leiden University Medical Center, NL

**Federico Innocenti** Section of Hematology / Oncology Assistant Professor of Medicine - Department of Medicine, Cancer Research Center, Committee on Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL

**Michael Lahn** Medical advisor, Program Phase Oncology Lilly GmbH - Bad Homburg, Germany

**Enrico Mini** Department of Preclinical & Clinical Pharmacology Operative unit of Pharmacology and Clinical Chemotherapy Service - University of Firenze

**Giuseppe Novelli** Director of Medical Genetics Laboratory Tor Vergata University Rome - PGWP EMEA London

**Carmine Pinto** Director of Medical Oncology Azienda Ospedaliera University - Trieste

**Antonella Pirazzoli** Director of Pharmacogenetics and Clinic Genetics - GlaxoSmithKline Spa - Pharmaceuticals - Verona

**Martin Potgeter** Director Corporate Business Development QIAGEN GmbH - Hilden, Germany

**Fabio Puglisi** Clinical Oncology - Breast Unit - University of Udine

**Mark J Ratain** Leon O. Jacobson Professor of Medicine Chairman, Committee on Clinical Pharmacology and Pharmacogenomics - Associate Director for Clinical Sciences, Cancer Research Center - The University of Chicago, Chicago, IL

**Carlo Riccardi** Elect President of Italian Society of Pharmacology - Professor of Pharmacology - Faculty of Medicine -